Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2017

30.06.2017 | Original Article – Clinical Oncology

Unmonitored use of herbal medicine by patients with breast cancer: reframing expectations

verfasst von: Noah Samuels, Eran Ben-Arye, Yair Maimon, Raanan Berger

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify the unmonitored use of herbal medicine by female patients with breast cancer, examining the impact of an integrative physician (IP) consultation on this practice.

Methods

The files of 269 female patients with breast cancer following an IP consultation were surveyed retrospectively for use of herbal medicine for cancer-related goals. Expectations from the IP consultation and adherence to the IP-guided treatments were examined as well.

Results

Among the cohort, 111 (41.3%) reported using herbal medicine for cancer-related goals, unmonitored by their oncology healthcare professional. Factors predicting herbal medicine use were the adoption of dietary changes (odds ratio = 13.6, p < 0.001, CI 7.16–26.0) and the expectation that the IP consultation and treatments would address cancer-related goals (odds ratio = 3.29, p = 0.001, CI 1.64–6.6). Patients with metastatic disease were more likely to be using herbal medicine than non-users (34.5 vs. 22.8%; p = 0.088), as were those who had consulted with a complementary/alternative medicine practitioner (54.9 vs. 20.8%; p = 0.005). The IP advised 17 patients (15.3%) to stop taking specific herbal products due to safety-related concerns; and 10 patients to take dietary supplements for relief of specific symptoms. Herbal medicine users were less likely than non-users to adhere to the IP-recommended treatment program (34.7 vs. 48.3%; p = 0.037).

Conclusions

Unmonitored use of herbal medicine by patients with breast cancer is more frequent among those adopting dietary changes for cancer-related goals. Integrative physicians provide evidence-based guidance on the safe and effective use of herbal products, and reframe patient expectations from cancer-related goals to reducing symptoms and improving quality of life.
Literatur
Zurück zum Zitat Barbuti AM, Chen ZS (2015) Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers Basel 7(4):2360–2371CrossRefPubMedPubMedCentral Barbuti AM, Chen ZS (2015) Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers Basel 7(4):2360–2371CrossRefPubMedPubMedCentral
Zurück zum Zitat Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105(16):1230–1238CrossRefPubMedPubMedCentral Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105(16):1230–1238CrossRefPubMedPubMedCentral
Zurück zum Zitat Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511CrossRefPubMed Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511CrossRefPubMed
Zurück zum Zitat Ben-Arye E, Kruger D, Samuels N, Keinan-Boker L, Shalom T, Schiff E (2014) Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting. Support Care Cancer 22(3):627–644CrossRefPubMed Ben-Arye E, Kruger D, Samuels N, Keinan-Boker L, Shalom T, Schiff E (2014) Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting. Support Care Cancer 22(3):627–644CrossRefPubMed
Zurück zum Zitat Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E, Charalambous H, Dweikat T, Ghrayeb I, Bar-Sela G, Turker I, Hassan A, Hassan E, Saad B, Nimri O, Kebudi R, Silbermann M (2016) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610CrossRefPubMed Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E, Charalambous H, Dweikat T, Ghrayeb I, Bar-Sela G, Turker I, Hassan A, Hassan E, Saad B, Nimri O, Kebudi R, Silbermann M (2016) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610CrossRefPubMed
Zurück zum Zitat Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4CrossRefPubMedPubMedCentral Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4CrossRefPubMedPubMedCentral
Zurück zum Zitat Corina G, Christine H, Klein G (2016) Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis. Support Care Cancer 24(9):3857–3862CrossRefPubMed Corina G, Christine H, Klein G (2016) Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis. Support Care Cancer 24(9):3857–3862CrossRefPubMed
Zurück zum Zitat Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72–79CrossRefPubMed Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72–79CrossRefPubMed
Zurück zum Zitat Deng G (2008) Integrative cancer care in a US academic cancer centre: the Memorial Sloan–Kettering experience. Curr Oncol 15(Suppl 2):s108.es68–s108.es71 Deng G (2008) Integrative cancer care in a US academic cancer centre: the Memorial Sloan–Kettering experience. Curr Oncol 15(Suppl 2):s108.es68–s108.es71
Zurück zum Zitat Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delblanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252CrossRefPubMed Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delblanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252CrossRefPubMed
Zurück zum Zitat Frenkel M, Cohen L, Peterson N, Palmer JL, Swint K, Bruera E (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283CrossRefPubMed Frenkel M, Cohen L, Peterson N, Palmer JL, Swint K, Bruera E (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283CrossRefPubMed
Zurück zum Zitat Haefeli WE, Carls A (2014) Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol 10(3):359–377CrossRefPubMed Haefeli WE, Carls A (2014) Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol 10(3):359–377CrossRefPubMed
Zurück zum Zitat Heller AR, Fischer S, Rossel T, Geiger S, Siegert G, Ragaller M, Zimmerman T, Koch T (2002) Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br J Nutr 87(Suppl 1):S95–S101CrossRefPubMed Heller AR, Fischer S, Rossel T, Geiger S, Siegert G, Ragaller M, Zimmerman T, Koch T (2002) Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br J Nutr 87(Suppl 1):S95–S101CrossRefPubMed
Zurück zum Zitat Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633CrossRefPubMedPubMedCentral Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633CrossRefPubMedPubMedCentral
Zurück zum Zitat Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, Muecke R, Loeser C (2014) Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anticancer Res 34(1):39–48PubMed Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, Muecke R, Loeser C (2014) Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anticancer Res 34(1):39–48PubMed
Zurück zum Zitat Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S (2017) A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Med Oncol 34(4):69CrossRefPubMed Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S (2017) A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Med Oncol 34(4):69CrossRefPubMed
Zurück zum Zitat Kulp KS, Montgomery JL, Nelson DO, Cutter B, Latham ER, Shattuck DL, Klotz DM, Bennett LM (2006) Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Res Treat 98:249–259CrossRefPubMed Kulp KS, Montgomery JL, Nelson DO, Cutter B, Latham ER, Shattuck DL, Klotz DM, Bennett LM (2006) Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Res Treat 98:249–259CrossRefPubMed
Zurück zum Zitat Lewith G, Aldridge E (eds) (1991) Complementary medicine and the European community. C.W. Daniel, Saffron Walden Lewith G, Aldridge E (eds) (1991) Complementary medicine and the European community. C.W. Daniel, Saffron Walden
Zurück zum Zitat Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13:555–562CrossRefPubMed Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13:555–562CrossRefPubMed
Zurück zum Zitat Prakash P, Misra A, Surin WR, Jain M, Bhatta RS, Pal R, Raj K, Barthwal MK, Dikshit M (2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 127(2):111–118CrossRefPubMed Prakash P, Misra A, Surin WR, Jain M, Bhatta RS, Pal R, Raj K, Barthwal MK, Dikshit M (2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 127(2):111–118CrossRefPubMed
Zurück zum Zitat Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, Livingston ML, Ruiterman J, Ampela R, Kaw OC, Blanchard C (2005) Patient–physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23:35–60CrossRefPubMed Roberts CS, Baker F, Hann D, Runfola J, Witt C, McDonald J, Livingston ML, Ruiterman J, Ampela R, Kaw OC, Blanchard C (2005) Patient–physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol 23:35–60CrossRefPubMed
Zurück zum Zitat Saibul N, Shariff ZM, Rahmat A, Sulaiman S, Yaw YH (2012) Use of complementary and alternative medicine among breast cancer survivors. Asian Pac J Cancer Prev 13:4081–4086CrossRefPubMed Saibul N, Shariff ZM, Rahmat A, Sulaiman S, Yaw YH (2012) Use of complementary and alternative medicine among breast cancer survivors. Asian Pac J Cancer Prev 13:4081–4086CrossRefPubMed
Zurück zum Zitat Shalom-Sharabi I, Samuels N, Lev E, Lavie O, Keinan-Boker L, Schiff E, Ben-Arye E (2017) Impact of a complementary/integrative medicine program on the need for supportive cancer care-related medications. Support Care Cancer. doi:10.1007/s00520-017-3726-4 Shalom-Sharabi I, Samuels N, Lev E, Lavie O, Keinan-Boker L, Schiff E, Ben-Arye E (2017) Impact of a complementary/integrative medicine program on the need for supportive cancer care-related medications. Support Care Cancer. doi:10.​1007/​s00520-017-3726-4
Zurück zum Zitat Shin SC, Choi JS (2009) Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 20(7):584–588CrossRefPubMed Shin SC, Choi JS (2009) Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 20(7):584–588CrossRefPubMed
Metadaten
Titel
Unmonitored use of herbal medicine by patients with breast cancer: reframing expectations
verfasst von
Noah Samuels
Eran Ben-Arye
Yair Maimon
Raanan Berger
Publikationsdatum
30.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2471-x

Weitere Artikel der Ausgabe 11/2017

Journal of Cancer Research and Clinical Oncology 11/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.